image credit: Adobe Stock

Sandoz to Build New Biologics Production Facility in Slovenia

Sandoz, the generics and biosimilars division of Novartis, announced on March 9, 2023 that it has signed a memorandum of understanding to build a new biologics production plant in Lendava, Slovenia. The company expects to invest at least $400 million in this project, which represents one of the largest international private-sector investments in Slovenia, according to a company press release.

Work on the new plant is set to begin in 2023, and full operations are provisionally planned for late 2026. The facility will support the increasing global demand for biosimilars.

Read More on Biopharm International